Table 2. Univariate analysis of time to local progression with death as competing risk.

		p-value	sHR	95% CI
Age		0.053	0.25	0.064-1.02
Gender	Male	0.7	0.87	0.43-1.76
	Female
ECOG	0	0.96	1.02	0.51-2.03
	> 0
Pump		0.68	1.14	0.60-2.16
Hepatic surgery		0.2	0.65	0.33-1.26
Anti-EGFR antibody		0.83	0.92	0.42-2.01
Anti-VEGF		0.6	0.84	0.43-1.62
CEA		0.2	1.09	0.95-1.26
Glass beads		0.35	1.33	0.73-2.43
Stasis		0.84	0.93	0.46-1.87
Tumor volume		0.23	1.14	0.92-1.4
Largest lesion		0.35	1.33	0.73-2.42
Number of lesions	≤ 3	0.15	1.69	0.83-3.42
	> 3
MAPK pathway		0.12	1.71	0.87-3.37
PI3K pathway		0.031	0.31	0.11-0.90

Abbreviations: sHR=subdistribution hazard ratio, CI=confidence interval.